The Brief Reports on natalizumab were referred to Biogen Idec, the manufacturer, which offers the following response: After learning of one confirmed and one suspected case of progressive multifocal ...

Over the next month, the weakness progressed to flaccid paralysis of the right arm and the patient had a seizure. Repeat MRIs showed progression of confluent hyperintense white-matter lesions ...

February 19, 2009 — Three deaths from progressive multifocal leukoencephalopathy (PML) and a possible fourth case have been reported in patients taking the immunosuppressant drug efalizumab (Raptiva, ...

Please provide your email address to receive an email when new articles are posted on . Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

A 34 year-old HIV positive man had declined anti-viral treatment. Over the course of 3 weeks, he developed progressive ataxia affecting the left side. Progressive Multifocal Leukoencephalopathy (PML): ...

New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of ...

Progressive multifocal leukoencephalopathy (PML) is usually a fatal neurological disease. The natural history of PML in patients with human immunodeficiency virus infection was analyzed. The ...

Opportunistic infections of the CNS, such as cryptococcal meningitis, cerebral toxoplasmosis, and tuberculous meningitis, are a major cause of morbidity and mortality in HIV-positive individuals ...

A 55-year-old right-handed man with no past medical history presented with a two week history of headache and progressive aphasia. He was found to be HIV positive, with HIV-1 RNA PCR showing 293,000 ...

After a century of futility in the treatment of multiple sclerosis, there is now a deluge of drugs that alter the course of the disease. The half-dozen new oral drugs have excited the most interest, ...